Medsafe replicates in part or in whole the drug approval processes of its overseas counterparts. There is expedited processing for drugs already approved overseas.
Every day in which a drug approval application is sitting on the desk of a bureaucratic at Medsafe is a day in which another New Zealander may die but for that drug.
That delay in access to drugs because of the duplication in approval processes is the invisible graveyard of Medsafe. My Official Information Act requests so far have been unable to access a cost benefit analysis at the Ministry of Health that quantifies the size of that invisible graveyard.
If economists have a bitter drinking song it would be “how many people has the FDA killed today”. Many drugs became available years after they were on the market outside the USA because of drug approval lags at the FDA. The dead are many. To quote…
View original post 645 more words